LRG1 molekülünün sklerodermadaki rolü, skleroderma klinik bulgular i̇le kolerasyonu, TGFβ, VEGF, IL-6, TNF α düzeyleri̇ i̇le ilişkisi
Yükleniyor...
Dosyalar
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Hatay Mustafa Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Çalışmamızın amacı LRG1 molekülünün sklerodermadaki rolünü, skleroderma klinik bulgular ile korelasyonunu ve TGFβ, VEGF, IL-6, TNF‐α düzeyleri ile ilişkisini incelemektir. Materyal ve Metot: Prospektif çalışmanın örneklemi, Eylül 2020 – Eylül 2021 ayları arasında Hatay Mustafa Kemal Üniversitesi Tıp Fakültesi Hastanesi Romatoloji polikliniğinde SSc tanısı alan 40 hasta ve 40 sağlıklı birey kontrol grubunu oluşturdu. Çalışmaya katılan tüm hasta ve sağlıklı bireylerin serumunda LRG1, TGFβ, VEGF, IL-6 ve TNF‐α düzeyleri ölçüldü. Çalışmadan elde ettiğimiz bulgular istatistiksel olarak değerlendirildi. Bulgular: Çalışmamızda hasta ve kontrol grubu arasında LRG1, TGFβ, VEGF, IL-6 ve TNF‐α düzeyleri açısından istatistiksel olarak anlamlı bir farklılık tespit edildi. Hastaların LRG1 ortalaması 253,99±52,26, kontrol grubunda yer alan bireylerin LRG1 ortalaması ise 189,18±30,67 idi (p<0,001). Hastaların TGF-β ortalaması 548,95±588,93, kontrol grubunda yer alan bireylerin TGF-β ortalaması ise 310,68±101,80 idi (p=0,016). Hastaların TNF‐α ortalaması 180,40±142,31, kontrol grubunda yer alan bireylerin TNF‐α ortalaması ise 114,76±25,43 idi (p=0,003). Hastaların IL-6 ortalaması 44,58±36,05, kontrol grubunda yer alan bireylerin IL-6 ortalaması ise 28,53±6,56 idi (p=0,007). Hastaların VEGF ortalaması 747,96±562,36, kontrol grubunda yer alan bireylerin VEGF ortalaması ise 434,25±196,36 idi (p=0,022). LRG1 seviyeleri ile TNF-α arasında pozitif orta düzeyde bir korelasyon tespit edildi. SSc hastalarının LRG1 seviyeleri ile klinik bulguları arasında anlamlı bir ilişki tespit edilmedi. Yapılan ROC analizi neticesinde SSc hastalarının tanısında serum LRG1 düzeyinin başarılı bir performansa sahip olduğu tespit edildi. Sonuç: Çalışmamızda hasta ve kontrol grubu arasında LRG1, TGFβ, VEGF, IL-6 ve TNF‐α düzeyleri açısından istatistiksel olarak anlamlı bir farklılık tespit edildi. LRG1 seviyeleri ile TNF-α arasında pozitif orta düzeyde bir korelasyon tespit edildi. SSc hastalarının LRG1 seviyeleri ile klinik bulguları arasında anlamlı bir ilişki tespit edilmedi. LRG1'in SSc patogenezindeki rolünün belirlenmesi için prospektif tasarımda ve geniş hasta kohortunda yapılacak daha kapsamlı çalışmalara ihtiyaç vardır.
Aim: The aim of our study is to examine the role of LRG1 molecule in scleroderma, its correlation with scleroderma clinical findings and its relationship with TGFβ, VEGF, IL-6, TNF-α levels. Method: The sample of the prospective study consisted of 40 patients diagnosed with SSc in the Rheumatology outpatient clinic of Hatay Mustafa Kemal University Medical Faculty Hospital between September 2020 and September 2021 and the control group of 40 healthy individuals. LRG1, TGFβ, VEGF, IL-6 and TNF-α levels were measured in the serum of all patients and healthy individuals participating in the study. The findings obtained from the study were evaluated statistically. Results: In our study, a statistically significant difference was found between the patient and control groups in terms of LRG1, TGFβ, VEGF, IL-6 and TNF-α values. The mean LRG1 of the patients was 253,99±52,26, and the mean of LRG1 of the individuals in the control group was 189,18±30,67 (p<0,001). The mean TGF-β of the patients was 548,95±588,93, and the mean of TGF-β of the individuals in the control group was 310.68±101.80 (p=0,016). The mean TNF-α of the patients was 180,40±142,31, and the mean of TNF-α of the individuals in the control group was 114.76±25,43 (p=0,003). The mean IL-6 of the patients was 44,58±36,05, and the mean of IL-6 of the individuals in the control group was 28,53±6,56 (p=0,007). The mean VEGF of the patients was 747,96±562,36, and the mean VEGF of the individuals in the control group was 434,25±196,36 (p=0,022). A moderate positive correlation was detected between LRG1 levels and TNF-α. No significant correlation was found between LRG1 levels and clinical findings of SSc patients. As a result of the ROC analysis, it was determined that the serum LRG1 level had a successful performance in the diagnosis of SSc patients. Conslusion: In our study, a statistically significant difference was found between the patient and control groups in terms of LRG1, TGFβ, VEGF, IL-6 and TNF-α values. A moderate positive correlation was detected between LRG1 levels and TNF-α. No significant correlation was found between LRG1 levels and clinical findings of SSc patients. More comprehensive studies are needed in a prospective design and in a large patient cohort to determine the role of LRG1 in the pathogenesis of SSc. Key words: Systemic sclerosis, scleroderma, LRG1, TGFβ, VEGF, IL-6, TNF‐α
Aim: The aim of our study is to examine the role of LRG1 molecule in scleroderma, its correlation with scleroderma clinical findings and its relationship with TGFβ, VEGF, IL-6, TNF-α levels. Method: The sample of the prospective study consisted of 40 patients diagnosed with SSc in the Rheumatology outpatient clinic of Hatay Mustafa Kemal University Medical Faculty Hospital between September 2020 and September 2021 and the control group of 40 healthy individuals. LRG1, TGFβ, VEGF, IL-6 and TNF-α levels were measured in the serum of all patients and healthy individuals participating in the study. The findings obtained from the study were evaluated statistically. Results: In our study, a statistically significant difference was found between the patient and control groups in terms of LRG1, TGFβ, VEGF, IL-6 and TNF-α values. The mean LRG1 of the patients was 253,99±52,26, and the mean of LRG1 of the individuals in the control group was 189,18±30,67 (p<0,001). The mean TGF-β of the patients was 548,95±588,93, and the mean of TGF-β of the individuals in the control group was 310.68±101.80 (p=0,016). The mean TNF-α of the patients was 180,40±142,31, and the mean of TNF-α of the individuals in the control group was 114.76±25,43 (p=0,003). The mean IL-6 of the patients was 44,58±36,05, and the mean of IL-6 of the individuals in the control group was 28,53±6,56 (p=0,007). The mean VEGF of the patients was 747,96±562,36, and the mean VEGF of the individuals in the control group was 434,25±196,36 (p=0,022). A moderate positive correlation was detected between LRG1 levels and TNF-α. No significant correlation was found between LRG1 levels and clinical findings of SSc patients. As a result of the ROC analysis, it was determined that the serum LRG1 level had a successful performance in the diagnosis of SSc patients. Conslusion: In our study, a statistically significant difference was found between the patient and control groups in terms of LRG1, TGFβ, VEGF, IL-6 and TNF-α values. A moderate positive correlation was detected between LRG1 levels and TNF-α. No significant correlation was found between LRG1 levels and clinical findings of SSc patients. More comprehensive studies are needed in a prospective design and in a large patient cohort to determine the role of LRG1 in the pathogenesis of SSc. Key words: Systemic sclerosis, scleroderma, LRG1, TGFβ, VEGF, IL-6, TNF‐α
Açıklama
Anahtar Kelimeler
İç Hastalıkları, Internal diseases, Sistemik skleroz, skleroderma, LRG1, TGFβ, VEGF, IL-6, TNF‐α
